Megastril (Megestrol Acetate)

Megestrol Acetate binds to progesterone receptors, acting as an agonist, and also exhibits glucocorticoid‑like activity. This dual action influences hypothalamic pathways that control hunger, leading to increased appetite, while also modulating gene expression in estrogen‑dependent tumor cells to inhibit their growth.

The dose of Megastril is individualized and set by the prescribing clinician based on the patient’s condition, weight, and response. No fixed regimen is provided here; healthcare professionals determine the appropriate strength and frequency according to clinical guidelines.

Safety data for Megestrol Acetate in pregnancy and lactation are limited. Because it is a hormonal agent, it is generally avoided unless the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To request Megastril, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

The most common alternative for appetite stimulation is megestrol acetate’s sister compound, medroxyprogesterone acetate, and other agents such as dronabinol. Compared with medroxyprogesterone, Megastril generally offers similar progestogenic activity but may have a slightly stronger glucocorticoid effect, influencing weight gain and metabolic profile. Choice depends on individual tolerance, drug‑interaction profile and clinician preference.

Megastril should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in bathrooms or other humid environments.

Megastril is taken orally, usually with or without food as directed by the prescriber. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed.

Serious adverse events include thromboembolic complications such as deep‑vein thrombosis or pulmonary embolism, adrenal suppression leading to cortisol deficiency, severe hyperglycemia, and rare but life‑threatening allergic reactions like anaphylaxis or Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience sudden swelling, shortness of breath, severe fatigue, or signs of infection.

Megastril is contraindicated in patients with known hypersensitivity to megestrol acetate, active uncontrolled thromboembolic disease, severe uncontrolled diabetes, or those receiving systemic glucocorticoids where additive adrenal suppression could be hazardous. Caution is also advised for individuals with a history of cardiovascular disease, liver impairment, or active infections.